Abstract:Endometriosis (EMs) is a common benign gynecological disease, with a complex and diverse etiology. Ectopic endometrial lesions exhibit characteristics of malignant tumors, such as proliferation, adhesion, invasion, and migration, which seriously affect the physical and mental health of female patients. The specific pathogenesis of EMs is not yet clear, and previous studies have shown that the development of EMs is closely related to pathological processes including inflammation, oxidative stress, and angiogenesis. Silent information regulator 1 (SIRT1), as a histone deacetylase, may mediate immune inflammatory response, angiogenesis, oxidative stress, apoptosis, autophagy, epithelial-mesenchymal transition, and other processes by regulating the acetylation of histones and key transcription factors, and therefore play roles in the occurrence and development of EMs. In recent years, researches have found that some natural products may be able to prevent and treat EMs by targeting SIRT1 and its related pathways, and could be potential therapeutic agents for EMs in clinical practice. We summarize the underlying mechanisms by which SIRT1 is involved in the pathogenesis of EMs and discuss the potential of SIRT1 as a therapeutic target for EMs, as well as the effectiveness of related natural products as clinical drugs or dietary supplements, in order to provide new ideas and directions for identifying novel therapeutic targets for EMs and developing drugs with favorable pharmacodynamic properties against EMs.